Ibalizumab (CD4 D3 domain) - Research Grade Biosimilar
Product Specifications
Background
Ibalizumab (also known as ibalizumab-uiyk and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies 8,5.
Immunogen
Humanized / CD4 D3 domain [Homo sapiens]
Clonality
Recombinant Monoclonal
Conjugation
Unconjugated
Type
Primary Antibodies, Biosimilars
Source
CHO cells
Field of Research
Infectious Disease
Purification
>95%
Concentration
Batch dependent
Buffer
PBS buffer pH7.5
Modification
None
Shipping Conditions
Blue Ice
Storage Conditions
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.
Product Datasheet
https://www.prosci-inc.com/?datasheet_sku=10-262
Fragment
IgG4-kappa
NCBI Organism
Homo sapiens
Other Product Names
Hu5A8, TMB-355, TNX-355
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![HLAA (HLA-A) Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI2D11]](https://cdn.genprice.uk/genprice/genprice4.png)
TA813378AM 100 µL
HLAA (HLA-A) Mouse Monoclonal Antibody (Biotin conjugated) [Clone ID: OTI2D11]
Ask
View Details 
